Skip to main content
Premium Trial:

Request an Annual Quote

BGI Dx, Bioscience Genomics Ink NIPT Deal

NEW YORK (GenomeWeb) – BGI Dx, a subsidiary of BGI, and Italian firm Bioscience Genomics today announced they have signed a five-year framework agreement focused on non-invasive prenatal testing.

The agreement defines terms for the collaboration between the parties, as well as activities and exchanges, and specifically facilitates a technology transfer process for Bioscience Genomics' use of BGI's genetic sequencing technology platforms in the NIPT space.

The technology transfer will allow Bioscience Genomics to start offering NIPT services based on BGI's Nifty test. The test will be called the G-Test in Italy.

The cost related to the transfer of the technology, including setting up a laboratory, is €4.56 million ($5.81 million) with a total anticipated investment of €5.76 million.

Bioscience Genomics is a Rome-based spinout of Bioscience Institute in San Marino, Italy and Tor Vergata University in Rome. The firm offers prenatal diagnostics, newborn screening, and blood and cell banking services

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.